Skip to main content
S&P 5007,576.80-0.04%DOW52,156.93+0.75%NASDAQ25,341.34-0.38%BTC$76,856.00-1.09%ETH$2,248.17-0.35%GOLD$3,952.80+1.38%OIL$96.72-7.11%
Smart Investors Daily
SID Premium
EP

NASDAQ · EPRX

Eupraxia Pharmaceuticals Inc.

Healthcare · Biotechnology

$6.83

Down-$0.11 (-1.61%)

Updated Nov 2, 2026, 7:00 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
216.11M
P/E ratio
-7.17
Dividend yield
0.00%
52-week range
$5.25 – $9.32
Volume
1.22M
Avg. volume
144.03K

Price performance · EPRX

EPRX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

EPRX closed at $6.83 after 20 trading sessions, down 11.81% for the selected period.

Last close
$6.83
Period change
-11.81%
Period low
$6.59
Period high
$7.78
Daily close
View OHLC price history
EPRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$7.10$7.10$6.41$6.831.22M
Oct 29, 2026$7.44$7.51$7.10$7.251.02M
Oct 28, 2026$7.08$7.42$6.90$7.38419.99K
Oct 27, 2026$6.90$7.16$6.64$7.08486.21K
Oct 26, 2026$6.81$7.00$6.695$6.85540.29K
Oct 23, 2026$7.51$7.61$6.70$6.87348.8K
Oct 22, 2026$7.70$7.94$7.545$7.59391.89K
Oct 21, 2026$7.65$7.76$7.55$7.73348.32K
Oct 20, 2026$6.87$7.76$6.87$7.59938.69K
Oct 19, 2026$6.67$7.05$6.67$6.95398.53K
Oct 16, 2026$6.78$6.88$6.56$6.62582.91K
Oct 15, 2026$6.60$6.82$6.49$6.77594.85K
Oct 14, 2026$6.59$6.805$6.42$6.59278.23K
Oct 13, 2026$7.29$7.29$6.62$6.681.52M
Oct 12, 2026$7.46$7.56$7.2501$7.32250.67K
Oct 9, 2026$7.57$7.70$7.275$7.461.05M
Oct 8, 2026$7.69$7.75$7.34$7.57637.05K
Oct 7, 2026$7.64$7.88$7.475$7.78853.31K
Oct 6, 2026$7.81$8.07$7.67$7.741.64M
Oct 5, 2026$7.20$7.93$7.07$7.7451.77M

Latest EPRX news

The latest Smart Investors Daily articles mentioning EPRX.

Stock researchCompany · Overview

EPRX research

Overview

Company profile and research snapshot.

Company profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
EPRX recent ratings
DateFirmRatingTarget
Sep 23, 2026RAYMOND JAMES LTD.Strong Buy—
Aug 27, 2026WILLIAM BLAIR & COMPANYOutperform—
Aug 12, 2026RESEARCH CAPITAL CORPORATIONBuy—
May 22, 2026RAYMOND JAMES LTD.Strong Buy—
May 21, 2026RAYMOND JAMES LTD.Strong Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company’s management team will participate in the following upcoming conferences and host a virtual Analyst Day: Craig Hallum Biotech Cat

Yahoo · Oct 15, 2026

Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis

Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trialThe Company has a statistical team who are doing periodic reviews of the unblinded data to ensure that the statistical assumptions and sample size on efficacy are adequate and do not need to be revised. These reviews have confirmed that the sample size as designed does not need to be adjustedWithin both parts of the RESOLVE trial (open-label Phase 1b/2a and placebo-contro

Yahoo · Oct 9, 2026

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company’s ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By